$7.62
3.25%
Nasdaq, Nov 06, 04:00 pm EST. Closed.
ISIN
US75901B1070
Symbol
RGNX

REGENXBIO, Inc. Stock News

Neutral
●
PRNewsWire
●
2 days ago
RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q1 2027, with potential accelerated approval in 2H 2027 Topline data from pivotal subretinal wet AMD studies, ATMOSPHERE ® and ASCENT ® , expected in Q4 2026 Phase IIb/III NAAVIGATE trial for diabetic retinopathy ongoing Webcast today at 8:00 a.m. ET ROCKVILLE, Md.
Neutral
●
PRNewsWire
●
4 days ago
ROCKVILLE, Md., Nov. 3, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the Stifel 2026 Healthcare Conference.
Neutral
●
PRNewsWire
●
26 days ago
Event to include clinical program overview and perspectives from leading retina specialists ahead of topline pivotal data readout anticipated in 4Q 2026 ROCKVILLE, Md., Oct. 12, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will host an investor event at 1:00 p.m.
Neutral
●
PRNewsWire
●
about one month ago
Majority of Dose Level 3 participants with NPDR demonstrated a > 2-step DRSS improvement at 3 years post-one-time, in-office sura-vec gene therapy treatment, with no vision-threatening events and no additional treatment for diabetic retinopathy No IOI observed with short-course prophylactic topical steroids ROCKVILLE, Md., Sept. 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today annou...
Neutral
●
Business Wire
●
2 months ago
SAN DIEGO--(BUSINESS WIRE)---- $RGNX #BiotechInvesting--Johnson Fistel, PLLP is investigating potential claims on behalf of current, long-term shareholders of REGENXBIO Inc. (NASDAQ: RGNX) against certain of its officers and directors for alleged breaches of fiduciary duty. Shareholders who have held REGENXBIO shares continuously since prior to February 9, 2022, may have standing to seek corpor...
Neutral
●
PRNewsWire
●
2 months ago
ROCKVILLE, Md., Aug. 25, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the appointment of Greg Ciongoli to its Board of Directors, effective August 25, 2026.
Neutral
●
GlobeNewsWire
●
3 months ago
SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating REGENXBIO Inc. (NASDAQ: RGNX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws. If you purchased REGENXBIO securities and suffered losses, click here to join the investigation.

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today